Ligand price target raised to $250 from $244 at BofA

BofA raised the firm’s price target on Ligand (LGND) to $250 from $244 and keeps a Buy rating on the shares after Travere Therapeutics (TVTX) announced FDA approved Filspari’s sNDA for FSGS. A review of the label reveals no major surprises outside of a small narrowing of the indication to FSGS without nephrotic syndrome, but “importantly” no post-marketing requirements, the analyst tells investors.